COCP Overview

Cocrystal Pharma Presentation: Cocrystal Pharma's CFO and co-CEO, James Martin, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025, followed by a Q&A session.

Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases like influenza and COVID, utilizing unique technologies and expertise.

Stock Offering Details: Cocrystal Pharma has announced a registered direct offering of 2.76 million shares at $1.70 per share, alongside a private placement of unregistered warrants for up to 5.53 million shares at an exercise price of $1.50.

Financial Projections: The company expects to raise approximately $4.7 million from the offering, with potential additional proceeds of about $8.3 million if the warrants are fully exercised.

CC-42344 Antiviral Efficacy: Cocrystal Pharma's CC-42344 has demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza strain, being approximately 1,000-fold more potent than Tamiflu, with favorable safety and tolerability in initial studies.

Concerns Over Avian Influenza Spread: The emergence of H5N1 in dairy cows has raised concerns about potential human-to-human transmission, as evidenced by confirmed human cases linked to exposure, highlighting the need for effective treatments like CC-42344.

Cocrystal Pharma's Antiviral Developments: Cocrystal Pharma is advancing its antiviral product pipeline, particularly the oral pan-viral protease inhibitor CDI-988, which has shown broad-spectrum activity against norovirus and coronaviruses. The company plans to initiate a human challenge study for CDI-988 soon, aiming to provide effective treatment options for these viral infections.

Financial Performance Overview: In the first quarter of 2025, Cocrystal reported a net loss of $2.3 million, a decrease from $4.0 million in the same period of 2024, alongside reduced research and development expenses. The company's cash reserves were noted at $6.9 million as of March 31, 2025, reflecting ongoing efforts to maintain a capital-efficient business model.